Janai Carr-Ascher, M.D., Ph.D.
Development of a Phenotypically Diverse Sarcoma Pre-Clinical Disease Model to Identify Novel Therapeutic Approaches

May Cho, M.D.
Development of Oxaliplatin-DNA adduct formation as a biomarker in gastrointestinal malignancies

Amanda Kirane, M.D.
Assessment of immune phenotype and patterns of response to neoadjuvant oncolytic virus in high risk, resectable melanoma

Tzu-yin (Cindy) Lin, D.V.M., Ph.D.
Multi-functional bladder-targeting Nanoporphyrin medicated phototherapy to potentiate immunotherapy

Lorenzo Nardo, M.D., Ph.D.
Optimized PET/CT: Clinical applications in lung cancer

Mamta Parikh, M.D., M.S.
Pilot study evaluating safety of selinexor and its effect on XPO1 expression in bladder and renal cancers

Aaron Seth Rosenberg, M.D., M.S.
Evaluating High Dose Melphalan Pharmacokinetics, Predictors of Variability, and its’ effect on Toxicity and Efficacy

Guobao Wang, Ph.D.
School of Medicine Dean's Scholar in Clinical Oncology

One-stop shop multiparametric PET imaging of cancer treatment response and organ chemotoxicity for targeted therapy

Gustavo Barisone, Ph.D.
Phase I/II trial of FWGP in patients with NHL receiving rituximab therapy

Jenna Burton, D.V.M., M.S., DACVIM
Contributions of B-cell lymphoma microenvironment in the development of drug resistance

Robert Canter, M.D,. M.A.S., FACS
Exploring novel treatment approaches in soft tissue sarcoma

Luis Carvajal-Carmona, B.Sc., Ph.D.
Colorectal cancer gene discovery in Hispanics through whole genome sequencing

Megan Daly, M.D.
Extending the benefit of immunotherapy for metastatic non-small cell lung cancer with ablative radiation

Elizabeth David, M.D., FACS
Understanding decision-making for surgery in advanced stage non-small cell lung cancer patients

Brian Jonas, M.D., Ph.D.
A daunorubicin and cytarabine microdosing feasibility study in adult acute myeloid leukemia

Edward Kim, M.D., Ph.D.
Aurora kinase inhibition in pancreatic cancer

Maija Kiuru, M.D., Ph.D.
Molecular subtyping of nevi and melanoma to improve diagnostic accuracy and identify drivers of melanomagenesis

Jonathan Riess, M.D.
Overcoming resistance to epidermal growth factor receptor tyrosine linase inhibitors (EGFR-TKIs) by linking patient derived lung cancer xenotransplants to clinical trials

Thomas Semrad, M.D., M.A.S.
Eliminating resistance to anti-vascular endothelial growth factor (VEGF) therapy through translational clinical trials and alternative angiogenic pathway